CST3 and chronic kidney disease: In the CKD-PC collaboration, where 720,736 individuals had measures of cystatin C in addition to eGFRcr and urinary albumin/creatinine ratio, replacing the assessment of eGFRcr with eGFRcr-cys in the matrix of GFR categories resulted in several changes in risk distributions.